CN116966232B - Traditional Chinese medicine composition for treating phlegm-heat accumulated lung syndrome community-acquired pneumonia and application thereof - Google Patents
Traditional Chinese medicine composition for treating phlegm-heat accumulated lung syndrome community-acquired pneumonia and application thereof Download PDFInfo
- Publication number
- CN116966232B CN116966232B CN202311193576.XA CN202311193576A CN116966232B CN 116966232 B CN116966232 B CN 116966232B CN 202311193576 A CN202311193576 A CN 202311193576A CN 116966232 B CN116966232 B CN 116966232B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- community
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 29
- 210000004072 lung Anatomy 0.000 title claims abstract description 28
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 22
- 208000026435 phlegm Diseases 0.000 title claims abstract description 22
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 54
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 22
- 241000334154 Isatis tinctoria Species 0.000 claims abstract description 22
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 20
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 20
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 20
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 20
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 20
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 235000002226 Ranunculus ficaria Nutrition 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims description 6
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims description 6
- 239000008354 sodium chloride injection Substances 0.000 claims description 6
- NCGMIBYQHQSCGQ-PPHPATTJSA-M levofloxacin sodium Chemical compound [Na+].C([C@@H](N1C2=C(C(C(C([O-])=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 NCGMIBYQHQSCGQ-PPHPATTJSA-M 0.000 claims description 5
- 229940126673 western medicines Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000293861 Scrophularia nodosa Species 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 21
- 206010011224 Cough Diseases 0.000 abstract description 11
- 206010037660 Pyrexia Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 208000006673 asthma Diseases 0.000 abstract description 3
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- 241001530126 Scrophularia Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 8
- 108010074051 C-Reactive Protein Proteins 0.000 description 7
- 102100032752 C-reactive protein Human genes 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 108010048233 Procalcitonin Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 206010063659 Aversion Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000009929 lianhuaqingwen Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000015339 staphylococcus aureus infection Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010052319 Nasal flaring Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating community-acquired pneumonia with syndrome of phlegm-heat accumulating in lung, which is prepared from the following raw materials in parts by weight: 11-19 parts of dyers woad leaf, 11-19 parts of honeysuckle, 2-10 parts of mugwort leaf, 2-10 parts of cassia twig, 5-13 parts of earthworm, 5-13 parts of Chinese angelica and 8-16 parts of radix scrophulariae. Clinically, the formula of the invention has better treatment effect on the community-acquired pneumonia with the syndrome of phlegm-heat accumulated in the lung by combining with the conventional western medicine treatment, has no adverse reaction, and is also suitable for treating various pulmonary diseases with symptoms of repeated cough, excessive phlegm, asthma attack and fever or fever.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating community-acquired pneumonia with phlegm-heat accumulating in lung and application thereof.
Background
Community-acquired pneumonia (Community-acquired-pneumonia, CAP) refers to an infectious lung parenchymal inflammation that is caused by a variety of microorganisms such as bacteria, viruses, chlamydia, and mycoplasma, and is a disease that is developed outside hospitals. The main clinical symptoms are cough, with or without expectoration and chest pain, and the precursor symptoms mainly comprise rhinitis-like symptoms or symptoms of upper respiratory tract infection, such as nasal obstruction, nasal discharge, sneeze, dry throat, pharyngalgia, pharyngeal foreign body sensation, hoarseness, headache, dizziness, eye thermal expansion, lacrimation, mild cough and the like. Elderly patients more often show blurred consciousness or exacerbation of existing disease, usually without chest signs or fever.
In traditional Chinese medicine, there is no disease name of 'community-acquired pneumonia', but there is a disease of wind-warm disease recorded in the theory of typhoid fever, and the disease of 'fever and thirst without aversion to cold' is a warm disease, and if sweating is already, the disease is scorched, the disease is named wind-warm disease. "in the exogenous febrile disease (Cold) Ten: wind-warm syndrome is the disease, and is the most prevalent in spring and month and winter. Or aversion to wind or no aversion to wind, cough with polydipsia due to fever, and the outline of wind-warm syndrome. "Su Wen-thorn Heat" say: the patients with lung heat are firstly and gradually syncoped, and have vellus hair, aversion to wind-cold and yellow tongue. Fever, struggle with heat, dyspnea and cough, pain going through the chest and back, and headache. It can be seen that the symptoms of fever, cough, chest pain, etc. are similar to those of lung heat disease and wind-warm disease. Studies show that the phlegm-heat obstructing lung syndrome of wind-warm lung-heat disease has the most close relationship with the inflammatory index of patients, and the phlegm-heat obstructing lung syndrome refers to the excessive heat syndrome of lung channel caused by the accumulation of phlegm-heat in the lung and the failure of the lung to disperse and descend. Also known as phlegm-heat obstructing the lung. Clinically, cough, yellow and thick sputum with excessive quantity, chest distress, dyspnea with rough breath, even nasal flaring, or wheezing in the throat, dysphoria, fever and thirst, or cough with purulent, bloody and odorous sputum, chest pain, constipation, scanty and reddish urine, red tongue with yellow and greasy coating, slippery and rapid pulse.
At present, the general rule of traditional Chinese medicine treatment for CAP patients is clearing heat and detoxicating, ventilating lung and resolving phlegm, and the literature (Chen Zhi, chen Biha, yuan Lili, etc.) discloses the following formula in the observation of the curative effect of Jiawei Maxingshi Ganman decoction for treating community-acquired pneumonia (phlegm-heat obstructing lung) [ J ]. Chinese traditional Chinese medicine emergency, 2010 (05): 725-726): the flavored sesame-apricot-licorice decoction has definite curative effect on treating the disease and can reduce the level of inflammatory factors. Another document (Zhengling, fangqiang, lianhua qingwen granule for treating 46 cases of phlegm-heat obstructing lung type community-acquired pneumonia [ J ]. Zhejiang J.Chinese medicine, 2013 (11): 1) discloses that the use of Lianhua qingwen granule for treating the phlegm-heat obstructing lung type community-acquired pneumonia has a treatment effect on the basis of the conventional Western medicine treatment.
Because community-acquired pneumonia is still a disease with high morbidity and mortality at present and seriously affects the physical health of people, the development of more drugs effective for the disease is very necessary, and the traditional Chinese medicine composition for treating community-acquired pneumonia with phlegm-heat accumulating in lung and the application of the traditional Chinese medicine composition are not reported at present.
Disclosure of Invention
The invention aims at providing a traditional Chinese medicine composition for treating community-acquired pneumonia, aiming at the defects in the prior art.
A second object of the present invention is to provide a pharmaceutical composition for the treatment of community-acquired pneumonia
The third object of the invention is to provide an application of the traditional Chinese medicine composition.
In order to achieve the first object, the invention adopts the following technical scheme:
a traditional Chinese medicine composition for treating community-acquired pneumonia is prepared from the following raw materials in parts by weight: 11-19 parts of dyers woad leaf, 11-19 parts of honeysuckle, 2-10 parts of mugwort leaf, 2-10 parts of cassia twig, 5-13 parts of earthworm, 5-13 parts of Chinese angelica and 8-16 parts of radix scrophulariae.
As a preferred example, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 13-17 parts of dyers woad leaf, 13-17 parts of honeysuckle, 4-8 parts of mugwort leaf, 4-8 parts of cassia twig, 7-11 parts of earthworm, 7-11 parts of Chinese angelica and 10-14 parts of radix scrophulariae.
More preferably, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 parts of dyers woad leaf, 15 parts of honeysuckle, 6 parts of mugwort leaf, 6 parts of cassia twig, 9 parts of earthworm, 9 parts of Chinese angelica and 12 parts of figwort.
More preferably, the traditional Chinese medicine composition is a foot bath traditional Chinese medicine composition.
More preferably, the foot bath composition is used by the following method: weighing the raw materials according to the weight proportion of any one of claims 1-3, decocting with water, performing foot bath, adjusting the water temperature to about 40 ℃ before sleeping for 30 minutes every day, and soaking for 20 minutes.
In order to achieve the second purpose, the invention adopts the following technical scheme:
The pharmaceutical composition comprises western medicines and any one of the traditional Chinese medicine compositions, wherein the western medicines are levofloxacin sodium chloride injection and ambroxol hydrochloride capsules.
In order to achieve the third object, the present invention adopts the following technical scheme:
The application of any one of the traditional Chinese medicine composition or the pharmaceutical composition in preparing medicines for treating community-acquired pneumonia.
As a preferred example, the community-acquired pneumonia is of the type of phlegm-heat-accumulated lung.
The compatibility of the invention is as follows:
The invention mainly treats the symptoms: syndrome of phlegm-heat accumulating in the lung; efficacy: clearing lung-heat, resolving phlegm, relieving asthma and dredging collaterals; and (3) square solution: fang Zhongjin honeysuckle flower has sweet and cold taste, is light in weight, can disperse and disperse, and can transmit heat to reach the surface; the dyers woad leaf is bitter and cold, can purge fire and cool blood, and can clear heat toxin in nutrient blood, is matched with honeysuckle to supplement each other, enhances the effects of clearing heat and detoxicating, and is ice-cold and directly folded, so that the dyers woad leaf is taken as a monarch drug; the radix scrophulariae is cold but not drastic, moist but not greasy, discharges and descends, can clear and tonify kidney yin, can treat lung and heat, detoxicate and eliminate fire, and is a ministerial drug; dang Gui can promote blood circulation and regulate nutrient, and can treat cough with dyspnea; lumbricus, pheretima, as an adjuvant drug, clears away heat and unblocks the flow of qi, relieves asthma and cough. The yin-blood-replenishing herbs are mostly greasy, cold and cool, and are not easy to be done, so the Chinese mugwort leaf and the cassia twig are used for activating yang and harmonizing pulse and dispelling phlegm and turbid waste heat; the whole formula has orderly principal and subordinate aspects, is suitable for moistening dryness, dredging blood vessels, moistening but not greasy, and eliminating dryness from damaging body fluids.
Detailed Description
The application is further described below in conjunction with the detailed description. It is to be understood that these examples are illustrative of the present application and are not intended to limit the scope of the present application. Further, it is understood that various changes and modifications of the present application may be made by those skilled in the art after reading the description of the present application, and such equivalents are intended to fall within the scope of the application as defined in the appended claims. Unless otherwise indicated, the technical means used in the examples are conventional means well known to those skilled in the art and commercially available usual instruments and reagents, and can be referred to in the molecular cloning test guidelines (3 rd edition) (scientific press), microbiological tests (4 th edition) (higher education press) and manufacturer specifications of the corresponding instruments and reagents.
EXAMPLE 1A Chinese medicinal composition of the invention
15 Parts of dyers woad leaf, 15 parts of honeysuckle, 6 parts of mugwort leaf, 6 parts of cassia twig, 9 parts of earthworm, 9 parts of Chinese angelica and 12 parts of figwort.
EXAMPLE 2A Chinese medicinal composition of the invention (II)
15 Parts of dyers woad leaf, 13 parts of honeysuckle, 8 parts of mugwort leaf, 2 parts of cassia twig, 13 parts of earthworm, 9 parts of Chinese angelica and 10 parts of figwort.
EXAMPLE 3 Chinese medicinal composition of the invention (III)
13 Parts of dyers woad leaf, 17 parts of honeysuckle, 2 parts of mugwort leaf, 10 parts of cassia twig, 9 parts of earthworm, 7 parts of Chinese angelica and 14 parts of figwort.
EXAMPLE 4 Chinese medicinal composition of the Invention (IV)
17 Parts of dyers woad leaf, 11 parts of honeysuckle, 10 parts of mugwort leaf, 6 parts of cassia twig, 7 parts of earthworm, 11 parts of Chinese angelica and 8 parts of figwort.
EXAMPLE 5A Chinese medicinal composition of the present invention (five)
11 Parts of dyers woad leaf, 19 parts of honeysuckle, 6 parts of mugwort leaf, 4 parts of cassia twig, 11 parts of earthworm, 5 parts of Chinese angelica and 16 parts of figwort.
EXAMPLE 6 Chinese medicinal composition of the present invention (six)
19 Parts of dyers woad leaf, 15 parts of honeysuckle, 4 parts of mugwort leaf, 8 parts of cassia twig, 5 parts of earthworm, 13 parts of Chinese angelica and 12 parts of figwort.
EXAMPLE 7 Chinese medicinal composition of the invention (seven)
15 Parts of dyers woad leaf, 17 parts of honeysuckle, 2 parts of mugwort leaf, 10 parts of cassia twig, 9 parts of earthworm, 7 parts of Chinese angelica and 14 parts of figwort.
EXAMPLE 8A Chinese medicinal composition (eight) of the invention
13 Parts of dyers woad leaf, 11 parts of honeysuckle, 10 parts of mugwort leaf, 6 parts of cassia twig, 7 parts of earthworm, 11 parts of Chinese angelica and 8 parts of figwort.
EXAMPLE 9 Chinese medicinal composition of the invention (nine)
17 Parts of dyers woad leaf, 19 parts of honeysuckle, 6 parts of mugwort leaf, 4 parts of cassia twig, 11 parts of earthworm, 5 parts of Chinese angelica and 16 parts of figwort.
EXAMPLE 10A Chinese medicinal composition of the invention (ten)
11 Parts of dyers woad leaf, 15 parts of honeysuckle, 4 parts of mugwort leaf, 8 parts of cassia twig, 5 parts of earthworm, 13 parts of Chinese angelica and 12 parts of figwort.
EXAMPLE 11 Chinese medicinal composition (eleven) of the invention
19 Parts of dyers woad leaf, 13 parts of honeysuckle, 8 parts of mugwort leaf, 2 parts of cassia twig, 13 parts of earthworm, 9 parts of Chinese angelica and 10 parts of figwort.
EXAMPLE 12 preparation of the Chinese medicinal composition of the present invention
The preparation is prepared and weighed according to the weight ratio in any of the above examples 1-11, and the foot bath is performed after water decoction. The foot bath is carried out for 30 minutes before sleeping every day, the water temperature is adjusted to about 40 ℃, and the foot bath is soaked for about 20 minutes.
Example 13 clinical efficacy experiment
1 Case Source
Clinical data are selected from 80 cases of community-acquired pneumonia, non-severe cases, and 80 cases of patients suffering from wind-warm lung-heat disease phlegm-heat accumulation in lung syndrome by traditional Chinese medicine differentiation, wherein the community-acquired pneumonia is treated in medical department and ward in the Jing'an area of Shanghai city 1 in 2022.
2 Diagnostic criteria
The case selection accords with the traditional Chinese medicine diagnosis standard of community-acquired pneumonia diagnosis and treatment guidelines (2022 edition) community-acquired pneumonia, non-severe western medicine diagnosis standard and community-acquired pneumonia traditional Chinese medicine diagnosis and treatment guidelines (2018 revision), and the traditional Chinese medicine syndrome differentiation belongs to phlegm-heat accumulated lung syndrome; the age range is 20 years to 70 years; patients informed consent, voluntary participation; exclusion criteria: meets the severe pneumonia standard; allergic to quinolones; allergic to the components of qing Jin Bao lung foot bath formula; combining severe cardiovascular and cerebrovascular diseases, liver diseases, kidney diseases, tumor diseases, hematopoietic diseases, etc.; mental disorder.
3 Cases data and groupings
The control group was divided into 40 cases and the treatment group was divided into 40 cases according to the completely random grouping principle. The two groups of patients had no significant differences in sex, age, presence or absence of basal disease, combined administration, and were comparable (P > 0.05) (see table 1).
Table 1 comparison of baseline data for two groups of patients
Note that: the P value of the sex, age, basic disease and combined administration condition before treatment of the two groups is more than 0.05.
Treatment regimen 4
Control group: the treatment of the disease was carried out according to the guidelines for diagnosis and treatment of community-acquired pneumonia (2021 edition) set forth by the respiratory disease institute of the Chinese medical society, using 50ml of levofloxacin sodium chloride injection: 0.25 g/bag (Hunan Koren pharmaceutical Co., ltd., national drug standard H20203719), 50ml intravenous drip, once daily; ambroxol hydrochloride capsule 30mg of capsule (Shanghai Xinyi balance pharmaceutical industry Co., ltd., national drug standard H20000282) is orally taken twice a day, and is subjected to symptomatic and antipyretic treatment when necessary.
Treatment group: based on the conventional Western medicine treatment of the control group (50 ml of levofloxacin sodium chloride injection: 0.25 g/bag (Hunan Colon pharmaceutical Co., ltd., national drug standard H20203719), 50ml of intravenous drip, once daily; +ambroxol hydrochloride capsules 30mg x 30 particles/box (Shang Xin Yi balance pharmaceutical Co., ltd., national drug standard H20000282) 30mg orally, twice daily), the composition is added to a Qing Jin Bao lung lavipeditum prescription for treatment: is prepared from 15 g of dyers woad leaf, 15 g of honeysuckle flower, 6 g of mugwort leaf, 6 g of cassia twig, g of earthworm, 9 g of Chinese angelica, 12 g of figwort root by decocting with water, and one dose is taken every day. Decocting in water for 30 min, cooling to 40deg.C, and soaking feet in the decoction to water depth exceeding that of ankle. Soaking for 30 min each time, once every night. The Chinese medicinal decoction pieces are provided by Chinese medicinal pharmacy in Chinese medicine hospital in Jing'an area of Shanghai city.
Treatment course: the treatment course of the treatment group and the control group is 7 days.
5 Observation index
The Chinese medicine syndromes are integrated: the integral changes of the traditional Chinese medicine symptoms before and after the two groups of treatments are compared. According to the clinical research guidelines of related respiratory diseases in the 'clinical research guidelines of new traditional Chinese medicine', an integral table of clinical symptoms of traditional Chinese medicine is formulated, and the integral table is scored according to the severity of symptoms, and the integral table is scored according to the normal, light, moderate and severe degree. Normally 0 point, slightly 1 point, moderately 2 points and severely 3 points. The patients were evaluated for changes in cough, expectoration, fever, chest pain, shortness of breath, dry mouth, distention in the stomach, or dry stool, and tongue and pulse were recorded descriptive without score.
Inflammation index: the changes in neutrophil%, C-reactive protein (CRP) and Procalcitonin (PCT) levels before and after treatment were compared in both groups.
Adverse reaction: and observing adverse reaction conditions such as rash, nausea, vomiting, dizziness and the like in the two treatment periods.
6 Clinical efficacy assessment criteria
Reference to the "guidelines for clinical research of New Chinese medicine" is made to the preparation of related content. The nimodipine method is adopted for calculation, and the formula is as follows: syndrome integral effective rate= (pre-treatment integral post-treatment integral)/pre-treatment integral x 100%;
clinical recovery: the clinical symptoms disappear or basically disappear, and the integral value of the symptoms after treatment is reduced by more than or equal to 95 percent compared with that before treatment;
the effect is shown: the clinical symptoms are obviously improved, and the integral value of the symptoms after treatment is reduced by more than or equal to 70 percent and less than 95 percent compared with that before treatment;
The method is effective: the clinical symptoms are improved, and the integral value of the symptoms is reduced by more than or equal to 30 percent and is less than 70 percent after treatment;
invalidation: the clinical symptoms are not improved, and the symptom integral value is reduced by less than 30% after treatment compared with the integral value before treatment;
Total clinical effective rate= (number of recovery cases + number of significant cases + number of effective cases)/total cases x 100%.
7 Statistics and analysis
The resulting data was processed using SPSS22.0 statistical software. If the measurement data accords with normal distribution and the variance is uniform, thenThe comparison between groups is shown by the t-test of two independent samples. The paired t-test was used for comparison before and after treatment in the group. If the normal distribution is not met, the inter-group comparison is performed by Mann-Whitney U test of non-parametric test, and the intra-group comparison is performed by Wilcoxon test of non-parametric test, expressed by median (M) and quartile (P25, P75). The count data are described in terms of frequency and percent (n%) using chi-square test. P < 0.05, the difference is considered statistically significant.
8 Results
8.1 Total integral comparison of symptoms in TCM before and after treatment of two groups of patients
Before treatment, the Chinese medicine syndrome integral of the two groups of patients has no obvious difference (P is more than 0.05), before treatment, the Chinese medicine syndrome integral of the two groups of patients is reduced compared with that before treatment, and the difference has statistical significance (P is less than 0.05). Wherein the improvement condition of the traditional Chinese medicine symptoms of the patients in the treatment group is better than that of the control group, and the difference has statistical significance (p is less than 0.05), as shown in table 2.
TABLE 2 total integral comparison of symptoms in TCM before and after treatment (x.+ -. S) for two groups of patients
Note that: ① P < 0.05 compared to prior to treatment in the same group; ② P < 0.05 compared to the control group.
8.2 Comparison of clinical efficacy after treatment of two groups of patients
The control group has 40 patients, 29 patients are effective and 11 patients are ineffective after treatment, and the total effective rate is 72.5%; the observed group of 40 patients is treated, and the effective rate is 36, the ineffective rate is 4, and the total effective rate is 90%. The total clinical effective rate of the two groups of patients is compared by chi-square test, and has statistical significance (p is less than 0.05). See table 3.
TABLE 3 comparison of clinical efficacy after treatment for two groups of patients (%)
Note that: the two groups are tested by a chi-square test, and P is less than 0.05.
8.3 Comparison of N%, CRP, PCT levels before and after treatment of the two groups
No significant difference (P > 0.05) compared to the pre-treatment N%, CRP, PCT levels for both groups; after treatment, the two groups of N%, CRP and PCT values were all reduced compared with the treatment before treatment, the difference was statistically significant (P < 0.05), wherein the two groups of CRP and PCT value improvement condition treatment groups were superior to the control group, the difference was statistically significant (P < 0.05), the two groups of N% improvement condition treatment groups were equivalent to the control group, and the difference was not statistically significant (P > 0.05), as shown in Table 4.
Table 4 comparison of N%, CRP and PCT levels (x.+ -. S) before and after treatment of both groups
Note that: ① P < 0.05 compared to prior to treatment in the same group; ② P < 0.05 compared to the control group.
8.4 Adverse effects after two groups of treatments
No obvious adverse reactions were observed before and after the two treatments.
Example 14 animal experiments
1. Experimental materials
1.1 Animals
60C 57/BL6J mice, weight (18-22) g, male and female halves, purchased from Shanghai Sipuler-BiKai laboratory animal Co.
1.2 Medicaments
The medicine of the first traditional Chinese medicine composition: reference example 1;
The medicine of the traditional Chinese medicine composition II: reference example 2;
drug of control group: 15 parts of dyers woad leaf, 15 parts of honeysuckle, 6 parts of mugwort leaf, 6 parts of ephedra herb, 9 parts of earthworm, 9 parts of prepared rehmannia root and 12 parts of dried rehmannia root, and the mixture is decocted with water for use;
Western medicine: levofloxacin sodium chloride injection (Hunan Koren pharmaceutical Co., ltd., national drug standard H20203719) and ambroxol hydrochloride capsule (Shanghai Yi balance pharmaceutical Co., ltd., national drug standard H20000282).
1.3 Major reagents
Staphylococcus aureus (Shanghai collection biotechnology center), tumor Necrosis Factor (TNF) -alpha, interleukin (IL) -6, and the like.
2 Method
2.1 Animal Molding
The staphylococcus aureus has become one of the main pathogens of iatrogenic pneumonia and community pneumonia at present, so the pathogen is selected for modeling. After the mice were adaptively fed for one week, 50 mice were randomly selected and divided into 4 groups of 10 mice each, respectively, the first group of the present invention, the second group of the present invention, the control group and the model group, the mice were anesthetized with diethyl ether, the mice were nasally infected with 30 μl of the formulated suspension droplets of staphylococcus aureus containing 2×10 9 Colony Forming Units (CFU), the remaining 10 mice were used as a blank group, and an equal volume of PBS was injected.
2.2 Experimental protocol
After 24 hours from the molding, the hair around the limbs of the mice was removed, and the molded five groups of mice were treated with conventional western medicines daily, and were intraperitoneally injected with 10 mg/(kg·d) +60 mg/(kg·d) of the sodium chloride injection of levofloxacin and the ambroxol hydrochloride capsule was intragastrically administered in the following manner:
The first group of the invention: the medicine in the first group of the invention is boiled for 30 minutes by slow fire, the towel is divided into four small blocks, the four small blocks are soaked in the medicine liquid, and the towel is taken out and applied to the dehairing place of the mice for 20 minutes when the water temperature is reduced to 38-40 ℃.
The invention is two: the medicine of the second group of the invention is boiled for 30 minutes by slow fire, the towel is divided into four small blocks, the four small blocks are soaked in the medicine liquid, and the towel is taken out and applied to the dehairing place of the mice for 20 minutes when the water temperature is reduced to 38-40 ℃.
Control group: boiling the medicine of the control group with slow fire for 30 minutes, dividing the towel into four small blocks, soaking in the medicine liquid, and taking out the towel and applying the towel to the dehairing place of the mice when the water temperature is reduced to 38-40 ℃ for 20 minutes.
Blank and model mice were applied to the hair removal site with a towel of distilled water at about 40 ℃ which was soaked.
The treatments were all treated for 1 week.
2.3 Detection index
After the administration is finished on day 2, the surviving mice are anesthetized, the lung lobe tissues are taken out, the abdominal aorta is taken out for blood taking, and the supernatant obtained by centrifugation is placed in a refrigerator at-80 ℃ for freezing for cytokine detection. TNF-alpha and IL-6 levels in mouse serum were determined according to the ELISA kit-attached instructions, respectively.
3 Statistical method
SPSS was used to statistically process the data. Metering data useThe method is characterized in that t-test is adopted by a normal distributor, and non-parametric rank sum test is adopted by a non-normal distributor; the counting data is represented by examples or percentages, the non-grade data is checked by chi-square, and the grade data is checked by rank sum. The difference of P <0.05 is statistically significant.
Results 4 results
The results of the TNF-alpha and IL-6 levels in the serum of mice are shown in Table 1, which shows that each group of mice in the model group died most during the course of the experiment. After dosing intervention, it was found that the levels of TNF- α and IL-6 were increased (P < 0.05) in the model group compared to the blank group; indicating that the immune response resulted in increased inflammatory factor release following a staphylococcus aureus infection. After the drug treatment, compared with the model group, the levels of TNF-alpha and IL-6 in the control group, the first group and the second group are obviously down-regulated, and all have obvious differences (P is less than 0.01). Compared with the control group, the down-regulation of TNF-alpha and IL-6 levels of the first group and the second group is more remarkable, and the statistical difference (P < 0.05) exists. The first and second groups of the invention have the effect of down-regulating the levels of TNF-alpha and IL-6 inflammatory factors of mice after the staphylococcus aureus infection, and the down-regulating trend of the group of the invention is most obvious (P is less than 0.05).
TABLE 1 TNF-. Alpha.and IL-6 expression levels (x.+ -. S, mmol/L) after administration in groups of mice
Note that: compared with the blank group, #P < 0.05; compared with the model group, delta P is less than 0.01; compared with the control group, O P is less than 0.05; p < 0.05 compared to the second group of the invention.
The foregoing is merely a preferred embodiment of the present invention, and it should be noted that modifications and additions may be made to those skilled in the art without departing from the method of the present invention, which modifications and additions are also to be considered as within the scope of the present invention.
Claims (5)
1. The pharmaceutical composition for treating community-acquired pneumonia is characterized by comprising western medicines and a traditional Chinese medicine composition, wherein the western medicines are levofloxacin sodium chloride injection and ambroxol hydrochloride capsules, and the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 11-19 parts of dyers woad leaf, 11-19 parts of honeysuckle, 2-10 parts of mugwort leaf, 2-10 parts of cassia twig, 5-13 parts of earthworm, 5-13 parts of Chinese angelica and 8-16 parts of radix scrophulariae, wherein the traditional Chinese medicine composition is a foot bath traditional Chinese medicine composition.
2. The pharmaceutical composition according to claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 13-17 parts of dyers woad leaf, 13-17 parts of honeysuckle, 4-8 parts of mugwort leaf, 4-8 parts of cassia twig, 7-11 parts of earthworm, 7-11 parts of Chinese angelica and 10-14 parts of radix scrophulariae.
3. The pharmaceutical composition according to claim 2, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 parts of dyers woad leaf, 15 parts of honeysuckle, 6 parts of mugwort leaf, 6 parts of cassia twig, 9 parts of earthworm, 9 parts of Chinese angelica and 12 parts of figwort.
4. Use of a pharmaceutical composition according to any one of claims 1-3 for the preparation of a medicament for the treatment of community-acquired pneumonia.
5. The use according to claim 4, wherein the community-acquired pneumonia is a phlegm-heat accumulating lung syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311193576.XA CN116966232B (en) | 2023-09-15 | 2023-09-15 | Traditional Chinese medicine composition for treating phlegm-heat accumulated lung syndrome community-acquired pneumonia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311193576.XA CN116966232B (en) | 2023-09-15 | 2023-09-15 | Traditional Chinese medicine composition for treating phlegm-heat accumulated lung syndrome community-acquired pneumonia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116966232A CN116966232A (en) | 2023-10-31 |
| CN116966232B true CN116966232B (en) | 2024-06-04 |
Family
ID=88476937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311193576.XA Active CN116966232B (en) | 2023-09-15 | 2023-09-15 | Traditional Chinese medicine composition for treating phlegm-heat accumulated lung syndrome community-acquired pneumonia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116966232B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108992597A (en) * | 2017-06-07 | 2018-12-14 | 钱玉洁 | A kind of footbath with traditional Chinese medicines packet of clearing lung and eliminating phlegm |
| CN210353359U (en) * | 2019-07-04 | 2020-04-21 | 南京市中医院 | Glove for peripheral neuritis caused by tumor chemotherapy patient |
| CN114010732A (en) * | 2021-11-08 | 2022-02-08 | 上海市静安区中医医院 | Traditional Chinese medicine composition for treating vertigo and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299723C (en) * | 2005-06-14 | 2007-02-14 | 毛顺卿 | Medicine for treating rhomboembolia type angiitis |
| CN109999109A (en) * | 2019-05-08 | 2019-07-12 | 河南中医药大学第一附属医院 | A kind of lavipeditum children's antipyretic Chinese medicine composition and application |
| CN112190638A (en) * | 2020-11-16 | 2021-01-08 | 上海市静安区中医医院 | Traditional Chinese medicine composition for treating insomnia after stroke in cerebral infarction recovery period and application thereof |
| CN112274581B (en) * | 2020-12-03 | 2021-10-15 | 上海市静安区中医医院 | Traditional Chinese medicine composition for treating cerebral apoplexy cognitive disorder diseases and application thereof |
-
2023
- 2023-09-15 CN CN202311193576.XA patent/CN116966232B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108992597A (en) * | 2017-06-07 | 2018-12-14 | 钱玉洁 | A kind of footbath with traditional Chinese medicines packet of clearing lung and eliminating phlegm |
| CN210353359U (en) * | 2019-07-04 | 2020-04-21 | 南京市中医院 | Glove for peripheral neuritis caused by tumor chemotherapy patient |
| CN114010732A (en) * | 2021-11-08 | 2022-02-08 | 上海市静安区中医医院 | Traditional Chinese medicine composition for treating vertigo and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 中西医结合治疗小儿病毒性肺炎98例疗效观察;李付强，等;社区医学杂志;-;20051230(第06期);第86-87页 * |
| 中西医结合治疗脑梗死恢复期气虚血瘀证的临床疗效;王安安，等;中西医结合心脑血管病杂志;20200225;第18卷(第04期);第661-663页 * |
| 大柴芩足浴方辅助治疗小儿肺炎喘嗽发热临床疗效观察;宋桂华，等;中国中西医结合儿科学;20170825;第09卷(第04期);第280-283页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116966232A (en) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011063553A1 (en) | Traditional chinese medicine for treating flu induced by flu virus including type a h1n1 virus | |
| WO2021227614A1 (en) | Pharmaceutical composition for clearing lung and pulmonary fibrosis and use thereof | |
| CN116966232B (en) | Traditional Chinese medicine composition for treating phlegm-heat accumulated lung syndrome community-acquired pneumonia and application thereof | |
| CN109157574B (en) | Traditional Chinese medicine composition for oral care of critically ill patients and oral care solution containing traditional Chinese medicine composition | |
| CN110585281B (en) | Children and adults common traditional Chinese medicine preparation for treating phlegm-heat obstructing lung and preparation method thereof | |
| CN109908304B (en) | Traditional Chinese medicine composition and application thereof, external traditional Chinese medicine preparation and preparation method thereof | |
| CN116531457B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and application thereof | |
| CN103463400B (en) | Chinese medicine composition for treating infantile asthma | |
| CN103656306A (en) | Traditional Chinese medicine for treating urinary tract infection | |
| CN114917287B (en) | Traditional Chinese medicine composition for treating allergic asthma, preparation method and application thereof | |
| CN108355106B (en) | Traditional Chinese medicine formula for ventilating lung and abating fever | |
| CN115252724B (en) | Traditional Chinese medicine composition for treating pharyngitis, product and preparation method | |
| CN116211993B (en) | Composition for treating senile chronic disease and its preparation method | |
| CN116159100B (en) | Application of Yanshu mixture in preparing medicine for treating upper respiratory tract virus infection | |
| CN107050340B (en) | Traditional Chinese medicine composition for treating necrotizing lymphadenitis and application thereof | |
| CN112107649B (en) | Traditional Chinese medicine composition for treating oral mucosa injury caused by antitumor drugs | |
| CN102233026B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN118384224A (en) | Gekko Swinhonis antipyretic drink, and preparation method and application thereof | |
| CN106309902B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis yin deficiency and internal heat syndrome | |
| CN115105566A (en) | Traditional Chinese medicine composition for treating laryngeal cough and application | |
| CN106728288B (en) | Cough relieving composition | |
| CN105560547B (en) | Traditional Chinese medicine composition for treating exogenous fever | |
| CN111265631A (en) | Traditional Chinese medicine composition for respiratory diseases and preparation method and application thereof | |
| CN116421660A (en) | Jin Puju effervescent tablet for treating upper respiratory tract infection wind-heat invading lung disease | |
| CN117503898A (en) | Traditional Chinese medicine composition for treating asthma and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |